跳至主要内容
临床试验/EUCTR2020-001723-13-FR
EUCTR2020-001723-13-FR进行中(未招募)1 期

A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV

GROUPE HOSPITALIER PARIS SAINT-JOSEPH0 个研究点目标入组 640 人开始时间: 2020年4月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
640

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Either more than 50 years of age with at least comorbidity (hypertension, diabetes, obesity, cancer, chronic renal disease, immunodeficiency) OR more than 70 years of age with or without comorbidity
  • 2) Laboratory proved infection by COVID-19 or radiological sign highly suggestive of COVID-19
  • 3) Respiratory symptoms (cough, chest discomfort, dyspnea)
  • 4) Affiliation to the social security system
  • 5) Able to understand and sign a written informed consent form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 320
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 320

排除标准

  • 1) Need for hospitalization
  • 2) Patient in long term facility
  • 3) Patient without concern confirmation of COVID-19 by laboratory test or chest CT
  • 4) Known hypersensitivity or contra-indication to the 3 experimental treatments (Azithromycin, Hydroxychloroquine, Lopinavir/Ritonavir)

研究者

相似试验